An article on a web site for Australian doctors describes the outcome of clinical trials for the Orqis Cancion system. The article says the trials "failed to provide any overall benefit compared with standard medical therapy in patients hospitalized with acute decompensated heart failure (HF)". It goes on to say "the study was stopped early" and "the safety monitoring board judged that the device group were unlikely to show any improvement in the primary efficacy endpoint or any of its components, and further patients assigned to the device would be at excess risk for bleeding".
Here is the article http://simply4doctors.com.au/current-news/international-healthcare-news/?itemId=2558588
And just in case that article left you with any doubt, this entry on the US National Institutes of Health clinical trials web site is pretty straight forward. The study was terminated because they projected neutral significance for primary composite efficacy endpoint.
http://clinicaltrials.gov/ct2/show/NCT00357591
Orqis is a private company so it is hard to determine the state of its finances but publically available information shows their 2008 revenue was only US $3.9M. It is reasonable to assume that Orqis would have earned revenue from the clinical trial so the failure of their clinical trial might put even that modest revenue figure under stress in future years.
Here is the financial information http://www.hoovers.com/Orqis-Medical-Corporation/--HD__ftsssyfhk,src__dbi--/free-co-dnb_factsheet.xhtml
About this news blog
The purpose of this blog is to allow the Ventracor Shareholder's Group to assist in the dissemination and sharing of information, and to allow legitimate debate on the items posted on the blog. No claim is made as to the accuracy or authenticity of the content.
Wednesday, June 10, 2009
Disclaimer
All are invited to post constructive comments on all blog topics.
The comments on the blog may be monitored, and the Ventracor Shareholder's Group reserves the right not to post or remove or moderate any comments which in its opinionare unlawful, threatening, defamatory, offensive, or obscene.
This "blog" has links to information on other web sites. The opinions expressed in these linked articles are those of the relevant authors.
This "blog" allows anyone from the public to post comments. Any views expressed in these comments are those of the relevant author.
The Ventracor Shareholders Group does not endorse the views or opinions expressed in the linked articles or comments.
The Ventracor Shareholder's Group does not accept any responsibility for any injury, loss or damage incurred by use of or reliance on the information.Anyone who wishes to have a comment or link removed from the website should email contact@saveventracor.com immediately.
The comments on the blog may be monitored, and the Ventracor Shareholder's Group reserves the right not to post or remove or moderate any comments which in its opinionare unlawful, threatening, defamatory, offensive, or obscene.
This "blog" has links to information on other web sites. The opinions expressed in these linked articles are those of the relevant authors.
This "blog" allows anyone from the public to post comments. Any views expressed in these comments are those of the relevant author.
The Ventracor Shareholders Group does not endorse the views or opinions expressed in the linked articles or comments.
The Ventracor Shareholder's Group does not accept any responsibility for any injury, loss or damage incurred by use of or reliance on the information.Anyone who wishes to have a comment or link removed from the website should email contact@saveventracor.com immediately.